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 Girona, 29th January 2010 
 
Dear Sir, 
 
I enclose the reviewed version of the manuscript entitled “Evaluation of Potential Breath 
Biomarkers for Active Smoking: Assessment of Smoking Habits” in order that it be 
considered for publication in Analytical and Bioanalytical Chemistry. 
In this study we statistically demonstrate the effectiveness of 2,5-dimethylfuran as specific 
breath biomarker of smoking status (a large population group of 204 volunteers has been 
analyzed). This compound has been able to confirm smoking status in more than 99.5% of 
samples, without being affected by smoking habits. The main advantage of our results is the 
possibility to use only the qualitative determination of 2,5-dimethylfuran to demonstrate the 
smoking status of a person, including very light smokers (only some cigarettes per week). 
The application of a new “in-house” micro-trap specially developed to determine VOCs at 
pptv levels in gaseous samples has allowed us to detect this compound at very low levels, 
some orders of magnitude bellow other breath studies. This has permitted us to detect this 
compound in all smoker breath samples, whereas other studies were only able to detect its 
presence after short exposure due to their higher limits of detection. 
Our results open new perspectives in breath analysis as, for the first time, we demonstrate 
that breath can be effectively used for screening of toxic substances consumption (e.g., 
tobacco in this case). When specific exogenous contaminants are found, a simple 
qualitative analysis can confirm the consumption. 
After introducing the very constructive comments and suggestions made by the reviewers, 
we considerer that the manuscript has improved significantly its scientific level. Moreover, 
the changes added has resulted in a more readable and comprehensible manuscript. 
   
I look forward to hearing from you. 
 
Yours sincerely, 
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ABSTRACT 
Different compounds have been reported as biomarkers of smoking habit, but, to date, there is no 
an appropriate biomarker for tobacco-related exposure because the proposed chemicals seem to be 
nonspecific or they are only appropriate for short-term exposure. Moreover, conventional sampling 
methodologies require an invasive method because blood or urine samples are required. The use of  
a micro-trap system coupled to GC-MS analysis has been found to be very effective for the non-
invasive analysis of volatile organic compounds in breath samples. The levels of benzene, 2,5-
dimethylfuran, toluene, o-xylene, and m- p-xylene have been analyzed in breath samples obtained 
from 204 volunteers (100 smokers, 104 non-smokers; 147 female, 57 male; ages 16 to 53 years). 
2,5-dimethylfuran was always below the limit of detection (0.005 ppbv) in the non-smoker  
population and always detected in smokers independently of the smoking habits. Benzene was 
only an effective biomarker for medium and heavy smokers, and its level was affected by smoking 
habits. Regarding the levels of xylenes and toluene they were only different in heavy smokers and 
after short-term exposure. The results obtained suggest that 2,5-dimethylfuran is an specific breath 
biomarker of smoking status independently of the smoking habits (e.g., short- and long-term 
exposure, light and heavy consumption) and so, this compound might be useful as a biomarker of 
smoking exposure. 
 
Keywords: breath biomarkers; smoking; 2,5-dimethylfuran; benzene 
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Introduction 
Cigarette smoke has been described as “a complex mixture of chemicals produced 
by the burning of tobacco and its additives” [1] or “a complex aerosol that 
includes a gas vapor phase and a particulate phase” [2]. The gaseous phase 
consists mainly of nitrogen and oxygen, the constituents of air. Several 
combustion products such as carbon monoxide (CO), carbon dioxide and nitric 
oxide are exclusively found in the gaseous phase. Compounds that are important 
due to their known toxicity or carcinogenic properties, such as 1,3-butadiene, 
formaldehyde, acetaldehyde, acrolein, benzene, hydrogen cyanide, and nicotine, 
are also found in this phase. Some other compounds, such as phenol and cresols, 
are partitioned between the particulate and the gaseous phases [3]. 
From a clinical point of view, there is a need to find suitable biomarkers of 
smoking status because some patients do not admit to be smokers and recognize 
to smoke a smaller number of cigarettes than real. Moreover, as smoking is a well 
recognized risk factor for some pathologies, including vascular and lung diseases, 
it is important to have a marker of smoking habit that might be used to determine 
the real risk of developing such a diseases. Different compounds have been 
proposed as possible biomarkers of exposure (“biomarkers of exposure are 
chemicals found in the body providing evidence of environmental exposure to that 
chemical or to a precursor chemical” [4]) to tobacco smoke, and several studies 
have tried to find a correlation between the compound chosen as a biomarker and 
proof of the habit of smoking [5-10]. The analysis of these compounds has been 
performed in different matrices including urine, blood, hair, saliva, and exhaled 
air. Although urine and blood are well-established matrices for the analysis of 
smoking related compounds, there is a delay in obtaining the results of the 
sampling and, in the case of blood, the test is invasive. Breath sampling presents 
the advantage that is non-invasive and have not the discomfort associated with the 
sampling of blood and urine [11-15]. Moreover, breath sample analysis is simpler 
since the matrix is less complex than blood or urine, no work-up is required and it 
can be applied to a wide range of compounds [15]. 
Several cigarette smoke compounds have been analyzed in exhaled breath as 
potential biomarkers of cigarette smoking. Since no metabolic activation occurs, 
the most widely analyzed biomarker in breath has been CO [16]. Alveolar CO 
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concentrations measured prior to and after every successive cigarette indicate that 
CO is accumulated in the human body with repeated smoking [17]. However, 
there is not a good correlation between reductions in CO concentration and the 
reduction in smoking [18], furthermore, CO can come from sources other than 
smoking, limiting the usefulness of CO as a biomarker of smoking exposure. 
Different volatile organic compounds (VOC’s) have also been proposed as 
smoking breath biomarkers. Benzene, which is a known carcinogen, is the most 
common VOC analyzed in exhaled breath as a potential biomarker of cigarette 
smoking. Benzene levels detected in exhaled breath of people who had recently 
smoked were found to be ten times greater than in non-smokers [19]. This 
compound has proved to be a good biomarker to indicate recent use of tobacco 
[20,21]. However, it has two main limitations. Firstly, benzene concentration in 
breath is heavily time-dependent and falls extremely rapidly reaching background 
or pre-exposure levels in relatively short times and, furthermore, large variability 
has been reported in different studies [20,22,23]. Secondly, the fact that benzene 
is also present in the exhaled breath of non-smokers and there are many different 
sources of benzene in the environment, such as cars and other polluters, makes it a 
poor biomarker for the gas phase, or as an indicator of passive smoking [22]. 
1,3-butadiene has also been proposed as a breath smoking biomarker [22] but the 
same disadvantage of a fast return to pre-exposure levels has been found. In fact, 
Sanchez and Sacks [24] found that this compound is eliminated from the 
respiratory tract in less than 30 minutes after smoking. 
In recent years, 2,5-dimethylfuran has been postulated as a strong indicator of 
smoking status [22,24-27] given that this compound is not normally present at 
detectable levels in the breath of non-smokers. Ashley et al. confirmed the 
discrimination power of this compound in blood samples [28]. Unfortunately, the 
sample size used in each study (ranging from 10 to 31 samples) makes it difficult 
to establish statistically significant correlations for biomedical considerations. The 
purpose of this study was to evaluate the behavior of different potential smoking 
biomarkers in breath samples and to asses smoking habits. 
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Materials and Methods 
Breath Collection 
Breath analyses were conducted in 204 healthy adult volunteers, who were 
randomly asked to participate in the study. Fifty-seven were men (27.9 %) and 
147 (72.1 %) women, and the mean age was 24.6 years (range 16-53). All 
participants were either employees or students of the University of Girona. 
Analyses were carried out between April 15th, 2008 and November 13th, 2008. 
Before taking breath samples, participants were informed regarding the nature of 
the test and the aims, and were asked to fill in a form with supplementary 
information (see Supplementary Materials). For the purpose of this study and to 
normalize answers to the question “are you a smoker?”, a person was considered 
to be a smoker when he/she admitted to a smoking habit of at least one 
cigarette/day. When a person smoked more occasionally, the answer of “non-
smoker” was required and the participant was requested to specify the extent of 
his/her tobacco use in the “Remarks” section. 
Given that the main objective of this study was to evaluate the possibility of 
finding a biomarker compound in breath samples that would allow a real 
determination of smoking status of an individual independently of the extent of 
their habit, no requirements related to the time after smoking or food and drink 
ingestion were made prior to breath sampling. 
The participants were asked to take a deep breath and then exhale into a Tedlar 
gas-sampling bag (SKC Inc, Eighty Four, PA, USA). Approximately 1.0 L of 
breath sample was obtained for each participant and it was analyzed immediately 
after collection (less than 2 minutes after) to avoid the loss of analytes in the bags. 
For each sample, 775 cm3 of breath were required for the chromatographic 
analysis (i.e. breath samples were moved through the microtrap over the course of 
25 minutes at a fixed flow rate of 31 cm3·min-1). Each sampling bag was cleaned 
with purified nitrogen several times before to collect a breath sample. In order to 
determine background effects due to contaminants from the walls of the bags, the 
last portion of nitrogen used in the cleaning process was analyzed in the same 
conditions as breath samples. Using this procedure, no detectable background 
levels of any of the target compounds were found in the Tedlar bags. Moreover, to 
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avoid contamination of the bags from breath samples, each bag was used for a 
maximum of five breath samples. 
It is known that significant changes in the concentrations of specific molecules in 
breath take place as a result of variations in ventilation parameters during 
sampling, and hyperventilation may occur when a breath sample is collected from 
spontaneously breathing subjects [29]. However, this study was not aimed at 
determining the amounts of compounds from metabolic sources but rather at 
developing a reliable and quantitative method with low detection limits that 
allows the determination of adequate breath biomarkers in order to establish 
smoking status. For this reason, spontaneously breathing subjects were used. In 
order to reduce dead-space air contamination, the first 2-3 s of exhalation were not 
collected in the sampling bag. Indoor air samples at the different locations where 
breath samples were obtained were also collected for background determination; 
2,5-dimethylfuran was not detected in any indoor sample and benzene levels were 
always at equivalent or slightly larger levels that those found in non-smoker 
samples.  
Breath Analysis 
Different VOCs were selected for evaluation as possible smoking biomarkers. 
Benzene was evaluated given that it is the VOC which has been most frequently 
proposed as a smoking biomarker in the literature. Toluene and xylenes were 
chosen because VOC emissions by cigarette smoke are usually dominated by 
benzene and these compounds [30]. 2,5-dimethylfuran was included as recent 
studies have showed its strong correlation with smoking status [22,24-28]. 1,3-
butadiene was not evaluated as it has been found that the elimination of this 
compound from the respiratory tract is fast and cannot be detected at the limits of 
detection levels of the instrumental method used in this study after 30 minutes of 
smoking [24]. 
For the analysis of breath samples, an “in-house” capillary thermal desorption 
device connected to a gas chromatograph (Focus GC, Thermo Scientific, 
Waltham, MA, USA) with mass spectrometry detection (DSQ II, Thermo 
Scientific) was used. The microtrap used in this study was specifically developed 
for the analysis of VOCs in breath samples at ppbv-pptv levels [27]. The device 
uses a 80-mm-long, 1.35-mm-i.d. tube made of a Ni-Co alloy (Inconel 600, Accu-
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Tube Corp., Englewood, CO, USA) The tube contains a graded ensemble of three 
commercial adsorbent materials. Each bed contains 2.5±0.2 mg of Carboxen 1000 
and Carbopack X (Supelco, Bellefonte, PA, USA) and 5.5±0.2 mg of Carbopack 
B (Supelco). The packed tube was preconditioned by heating at 300ºC for 4 h with 
a continuous flow of nitrogen (200 mL·min-1). To avoid memory effects, sampling 
and desorption flow were in opposite directions. Adsorption of  VOCs from 
breath samples was done at 22±1ºC. A fast heating pulse (1 s) at ~300ºC was 
enough to obtain quantitative thermal desorption of all retained compounds and 
send them as a sharp injection plug to the chromatographic column. Component 
separation was achieved by the use of a 30 m length of nonpolar 5% phenyl 95% 
dimethylpolysiloxane column with 0.25 mm ID and 0.25 µm film thickness (ZB-
5ms, Zebron, Phenomenex, Torrance, CA). The oven temperature program was as 
follows: 40ºC held for 2 min, then ramped at 10ºC/min to 270ºC and held for 2 
min. The MS analyses were carried out in full-scan mode, with scan range 40-200 
amu. Electron impact ionization was applied at 70 eV. Helium carrier gas was 
used, with a constant inlet pr ssure of 31 kPa, after purification for water vapor, 
hydrocarbons, and oxygen. The acquisition of chromatographic data was 
performed by means of Xcalibur software (v. 1.4, Thermo Electron). Table 1 
shows the list of the target compounds and details of the GC-MS analysis. The 
analytical equipment developed allowed the total analysis of each breath sample 
to be performed in less than 45 minutes. 
Chemicals 
All reagents were reagent grade (purity 99.0% or better) purchased from Sigma-
Aldrich (Steinheim, Germany). Stocks were prepared in 10 L Tedlar gas-sampling 
bags filled with nitrogen (nitrogen 5.0 -99.9990 purity- purified for hydrocarbons, 
oxygen and water vapor with specific trap filters) by injecting 1 to 2 µL of 
individual components. Calibration standards were prepared by taking a fixed 
volume of the stock gas with a gas tight syringe and diluting to 10 L with purified 
nitrogen in a Tedlar bag. Stocks and standards were freshly prepared for each 
calibration. The stability of the target compounds in the Tedlar bags was 
evaluated for the period used for calibration purposes (up to 3 hours): benzene, 
toluene and xylenes did not show any loss in this period, 2,5-dimethylfuran 
displayed losses lower than 5% after 3 hours. The “in-house” thermal desorption 
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unit control was provided by a 12-bit A/D board (PCI-1710HG, Advantech, 
Taiwan). 
Data Analysis 
Statistical analysis was performed using SPSS for Windows Version 15.0. For 
calculations of statistical significance, two-sided testing was used and P<0.05 was 
considered as significant. A Kolmogorov-Smirnov test was used to study the 
distribution of the compounds evaluated in the samples. The results indicate that 
the chosen analytes do not follow a normal distribution and so the Mann-Whitney 
test was used to compare the values found between smokers and non-smokers. 
The Spearman correlation was used to determine the correlations between the 
levels of compounds and  the daily intake of cigarettes and the time since smoking 
the last cigarette. 
Results and Discussion 
The breath of a healthy non-smoker may contain more than 200 different VOC’s 
[31]. Unfortunately, the majority of VOC’s from tobacco smoke are also normally 
found in non-smokers breath, which makes it difficult to find suitable breath 
biomarkers for smoking status. It has been reported that all evaluated compounds 
in this study have exogenous origin [32]. Taking into account all references cited 
in the present study, 2,5-dimethylfuran is the only compound in this study that has 
not been reported in non-smokers breath. 
Figure 1 shows typical chromatograms obtained in the analysis of breath samples 
from a smoker and a non-smoker. The target compounds were identified using 
qualifier ions and retention times. Scan detection was used in all analyses but the 
evaluation of these chromatograms were not adequate for complete breath 
analysis due to the large variation in the levels of each compound in these samples 
(i.e., acetone at ppmv level and other VOCs at ppbv to pptv levels). Monitoring of 
extracted ion chromatograms was used during data analysis to determine the 
target compounds. 
The evaluation of indoor air (inspiratory concentrations) in different common 
spaces of the science faculty (those places where breath samples were usually 
obtained) showed that indoor levels (n=12) did not show significant differences 
from non-smoker breath levels for toluene, benzene and 2,5-dimethylfuran (the 
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last has never been detected in indoor air samples). Xylenes, however, showed 
slightly higher concentrations in indoor air than in non-smoker samples and did 
not show significant differences with smoker breath levels. These first results 
suggest that xylenes might not be appropriate compounds to assess the smoking 
habits. 
Among the 204 participants in the study, 100 (49%) were smokers (72, 72%, were 
women and 28, 28%, men) and 104 (51%) were non-smokers (75, 72%, were 
women and 29, 28%, men). The concentrations of the evaluated compounds in 
smokers and non-smokers are shown in Table 2 and Figure 2. These results show 
that there were significant differences in the levels of the five compounds 
evaluated between the whole population of smokers and non-smokers (Table 2). 
The evaluation by gender, however, did not show any significant difference 
between the levels detected in male and female smokers for any of the evaluated 
compounds. 
Effect of daily consumption of cigarettes 
The evaluation of the data supplied by the smokers population shows that 44 
volunteers (44%) smoked less than 10 cigarettes/day, 19 (19%) claimed to smoke 
approximately 10 cigarettes/day, 27 (27%) smoked between 10 and 20 
cigarettes/day, and 10 (10%) smoked more than 20 cigarettes/day. There were 
three people (3%) who indicated that they normally smoke at least 1 cigarette/day 
but the time that had passed since their last cigarette was more than 24 hours 
when the sample was obtained. 
The effects of the daily intake of cigarettes was evaluated and a positive, although 
weak, significant correlation was found between the daily number of cigarettes 
smoked and the concentrations detected (Table 3). The correlations obtained gave 
the best results for benzene and 2,5-dimethylfuran. 
When analyzed by sex, it is interesting to note that concentrations of xylenes in 
men did not show any significant correlation with the parameter evaluated. In the 
case of women, correlations were significant for all compounds (r= 0.314 for o-
xylene, r=0.246 for m-,p-xylene, r=0.338 for toluene, r=0.407 for benzene, and 
r=0.413 for 2,5-dimethylfuran). 
When subgroup analysis was performed and the smokers population is reduced to 
only light smokers (≤7 cigarettes/day, 33 smokers), the differences were only 
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significant for 2,5-dimethylfuran and benzene. The results indicate a lack of 
specifity of xylenes and toluene as adequate smoking biomarkers, and it may be 
that these compounds are only useful for heavy smokers. Benzene gave better 
results and seems to be an effective breath smoking biomarker for light smokers. 
2,5-dimethylfuran was the most suitable compound to test as there were 
significant differences between smokers and non-smokers in all cases 
independently of the subgroup evaluated. 
Effect of time since smoking 
The evaluation of the data reported for the smoking population showed that 23 
smokers (23%) gave the breath sample after less than 5 minutes of smoking, 19 
(19%) between 5 and 30 minutes after smoking, 16 (16%) between 30 minutes 
and 1 hour, 22 (22%) between 1 and 4 hours, 14 (14%) between 4 and 15 hours, 3 
(3%) between 15 and 24 hours, and 3 (3%) more than 24 hours after their last 
cigarette. A negative significant correlation was found between the time since the 
last cigarette and concentrations detected (Table 3). As in the case of cigarette 
consumption, the correlations obtained gave the best results for benzene and 
2,5-dimethylfuran. 
When analyzed by sex, xylenes in men did not show any significant correlation 
and, in the case of women, correlations were significant for all compounds 
(r=-0.339 for o-xylene,, r=-0.457 for m-,p-xylene, r=-0.521 for toluene, r=-0.695 
for benzene, and r=-0.751 for 2,5-dimethylfuran). 
These results show that levels of VOC contaminants present in the breath of 
smokers are affected by smoking habits. Note that information about smoking 
habits was obtained from questionnaire answers and, although these were 
anonymous, they may not always correspond to the exact conditions. 
Different studies have evaluated the effect of  time since smoking on the levels of 
benzene in breath samples [20-23], and conclude that benzene concentration in 
breath is heavily time-dependent and falls extremely rapidly immediately after 
each puff is taken. Moreover, the time required for benzene concentrations to 
return to pre-exposure levels varied largely from one study to another. Gordon et 
al. [22] reported a time of approximately 15 minutes whereas Jordan et al. [23] 
found that a time of around 1 h was needed. Jo and Pack [20] evaluated two 
kinetic models and found a mean half-life of 38.9 min with the one-compartment 
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model, and 11 min for the first half-life and 235 min for the second half-life with 
the two-compartment model. 
The results obtained in the present study also showed this fast return to pre-
exposure levels in breath content and it took place for the five compounds 
evaluated (Figure 3).The evaluation of the expiration decay curves showed that 
the evaluated compounds returned to pre-exposure levels in smokers in a range 
from 45 minutes to two hours for all samples evaluated, after which levels were 
equivalent to those in non-smokers. Moreover, there was large variability in the 
time needed to return to pre-exposure levels for each individual. It is necessary to 
note that all volunteers who agreed to participate in this test (n=3) had a daily 
consumption of cigarettes of less than 5 per day. Therefore, the results obtained 
cannot be used to determine that subjects with a large cigarette consumption need 
less than 2 hours to return to pre-exposure levels. 
Evaluation of the decay curves shows that there are certain differences in the 
behavior of the different VOCs. The curves obtained for benzene, toluene, and 
2,5-dimethylfuran showed the same tendency for all individuals evaluated (n=3). 
There was an immediate rapid fall in the levels of these compounds in the breath 
and thereafter a more gradual decrease. Xylene curves, however, showed different 
trends and there were large variations in their behavior from one subject to 
another. The differences in the concentration for xylenes between smokers and 
non-smokers were the smallest (<2 times greater in smokers), which led to a fast 
return to pre-exposure levels. Moreover, in some samples there was no decay in 
the post-exposure curves as the pre-exposure levels were at the same range as 
after smoking. This is explained by the fact that, as seen before, xylene 
concentrations detected in light smokers are frequently equivalent to those levels 
found in non-smokers. In these conditions, there is not a fast decay in xylene 
content as takes place with benzene, toluene and 2,5-dimethylfuran. 
Jo and Pack [20] indicated that the variability in concentration decay could be 
explained by the difference in the metabolism of the subjects. Our results also 
indicate that daily intake and background levels remaining in the respiratory 
system from earlier smoking have a considerable effect on the variability in the 
VOC content observed. The decay curves obtained for benzene and toluene 
showed that a time of between one and two hours was required to return to pre-
exposure levels for the subjects evaluated (light smokers). Those people typically 
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smoke one cigarette every two to three hours and so levels found before smoking 
a cigarette could be considered background levels. However, heavy smokers tend 
to smoke one cigarette every 20-30 minutes, at time which is not sufficient for a 
drop to background levels to be reached. 
The decay in the content found with the time since smoking makes necessary to 
compare the VOCs content in smokers and non-smokers at different time intervals 
after smoking. As showed previously, there was a significant difference between 
the values obtained for smokers and non-smokers was obtained for the five 
compounds tested when the whole population of smokers was used and no time 
subgroups were taken into account (Table 4, ≥0 min). Concentrations found for 
smokers and non-smokers were not significantly different in the case of xylenes 
and toluene when the subgroup of smokers used in the analysis only considered 
those people that gave the breath sample 45 minutes or more after smoking (43 
smokers). Benzene showed a larger time interval and it gave significant 
differences between smokers and non-smokers until approximately 12 hours of 
smoking. 2,5-dimethylfuran showed significant differences between the two 
groups in all the time intervals evaluated. This compound gave significant 
differences between smokers and non-smokers after more than 24 hours without 
smoking. 
Combined effects 
The wide variation found in the levels of benzene, toluene and xylenes between 
smokers with different consumption habits together with the fact that these 
compounds are also detected in the breath of non-smokers suggests that a large 
number of false negatives might be obtained with light smokers. 
In the specific case of xylenes and toluene another drawback is that they are only 
effective for recent exposure conditions. In the samples evaluated, these 
compounds lost their ability to adequately determine smoking status 
approximately 45 minutes after smoking (Table 4, Figure 2d). Furthermore, it was 
found that the test was less effective for subjects who smoked fewer cigarettes 
(<30 minutes for individuals that smoked <10 cigarettes/day, no differences at any 
time when intake was reduced to <7 cigarettes/day). 
Benzene, on the other hand, gave better time intervals and it could be used as an 
effective breath biomarker for some hours after smoking even in conditions of 
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13 
reduced cigarette consumption. Unfortunately, however, benzene is also present in 
the breath of healthy non-smokers and the significance of this compound is 
reduced in light smoking conditions and after 1-2 hours of smoking. 
2,5-dimethylfuran was detected in all smokers breath samples and it was only 
detected in 12 non-smokers samples (12% of the non-smoking population and 
5.9% of the total population). An exhaustive study of these 12 samples showed 
that four subjects indicated in the survey that they smoked less than one cigarette 
a day but smoked during weekends or on special occasions (i.e., social smokers): 
two of them claimed that they had smoked their last cigarette two days earlier; 
another, three days earlier; and the last one, five days earlier. When the 
concentrations of these subjects were introduced in the group of smokers for the 
calculations, the levels detected for 2,5-dimethylfuran still showed significant 
differences with non-smokers, and all other compounds, including benzene, 
showed no significant differences. Seven more subjects considered themselves to 
be passive smokers as they lived with people who smoked and said that they had 
been in contact with tobacco smoke in the previous hour before the sample was 
obtained. 2,5-dimethylfuran was detected in the sample of only one subject who 
claimed to be neither an active nor a passive smoker. 
The best results in all conditions evaluated (i.e., short and long exposure, light and 
heavy cigarette consumption) were obtained with 2,5-dimethylfuran (Figure 2a). 
Previous studies [22,24-27,32] have indicated that this compound has a high 
discrimination power as smoking breath biomarker. As can be seen in Table 4, 
this compound yielded significant differences in all conditions evaluated and 
maintained its significant difference between smokers and non-smokers during the 
whole time interval evaluated. Moreover, this compound is able to detect smoking 
status more than 24 hours after smoking for people with a very light smoking 
habit. 
The American National Research Council identifies different criteria for the 
establishment of an effective environmental tobacco smoke tracer. The first is 
“uniqueness” [33], a criterion which is also strongly recommended for an 
adequate smoking breath biomarker. 2,5-dimethylfuran has the advantage of not 
being an endogenous substance and that it can only be introduced in the 
respiratory system from exogenous sources: smoking is practically the only 
realistic source of this contamination. Moreover, recent studies have shown that 
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2,5-dimethylfuran emissions do not differ by cigarette type [30]. The results 
obtained in the present study show that this compound yields significant 
differences between smokers and non-smokers in all conditions evaluated (e.g., 
short- and long-exposure, light and heavy consumption). Furthermore, 2,5-
dimethylfuran maintains its ability to differentiate between smokers and non-
smokers even in the case of people who only smoke very occasionally, a situation 
in which benzene levels are unable to determine the true smoking status.  
Effect of smoking controlled substances 
A large proportion of the volunteers participating in the study were students and 
many of them referred to smoking controlled substances. Thirty-five subjects 
admitted to smoking cannabis. Of these, 28 were also cigarette smokers and gave 
positive results in the analysis of 2,5-dimethylfuran. Seven subjects claimed only 
to smoke pure cannabis, without mixing this with tobacco. Six of these seven 
people gave negative results in the analysis of 2,5-dimethylfuran whereas the 
seventh person was a passive smoker who had had recent contact with tobacco 
smoke. 
These results indicate that other drugs commonly related with smoking did not 
yield false positive results and confirm that 2,5-dimethylfuran is a specific breath 
biomarker for tobacco consumption. This compound has also demonstrated its 
effectiveness in detecting passive smoking when direct contact with the smoke 
has been produced just before a sample is analyzed. This makes 2,5-dimethylfuran 
a very promising biomarker as it is only necessary to detect its presence in order 
to be able to establish smoking status. 
Conclusions 
Here, we showed that toluene and xylenes can only be used as potential breath 
biomarkers of smoking exposure for those smokers with a large daily 
consumption of cigarettes (≥ 10 cigarettes/day) as well as recent exposure (less 
than 45 minutes after smoking). Benzene gave better results and could be used 
successfully as a biomarker with lower cigarette consumption (at least 1 
cigarette/day) and functions for a longer period after smoking (12-13 hours). The 
best results, however, were obtained with 2,5-dimethylfuran. This compound can 
be used as a breath biomarker of the smoking status also for social smokers (a 
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subgroup that is never considered as smokers due to their low cigarette 
consumption: 3-4 cigarettes/week) and is still effective long after the exposure 
(more than 24 hours after smoking). Moreover, 2,5-dimethylfuran is the only 
compound that is able to detect heavy passive smoking. 
The results obtained in this study suggest that further attempts to evaluate whether 
there exist some correlation with the food ingestion or cigarette type smoked 
would be fruitful. Moreover, studies about second hand smoke exposure are 
needed to determine the exposure conditions required to detect 2,5-dimethylfuran 
in passive smokers. 
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Figure 1. GC-MS chromatograms of exhaled breath from a smoker (a) and a healthy non-smoker 
person (b). Chromatograms were extracted at m/z= 78, 91 and 96 to facilitate the view of the target 
compounds. Y-axis scale was the same for both chromatograms.  
1: benzene; 2: 2,5-dimethylfuran; 3: toluene; 4: m- , p-xylene; 5: o-xylene. 
Other compounds identified in the chromatograms: a: acetone; b: alkane (C5); c: dichloromethane;   
d: alkane (C6); e: ethylbenzene; f: α-pinene; g: phenol; h: trimethylbenzene; i: limonene; j: 
eucalyptol. 
 
Figure 2. Box plots of data obtained for (a) 2,5-dimethylfuran, (b) benzene, (c) toluene, and (d) 
toluene when the subgroup of analysis for smokers only took into account those people that had 
smoked at least 120 minutes before. The bottom and top of the box are 25th and 75th percentiles, 
the line inside the box is the median (50th  percentile) and the whiskers indicate the lowest and 
highest data within 1.5 inter-quartile range. 
 
Figure 3. Normalized decay curves obtained for benzene, 2,5-dimethylfuran, toluene, and 
o-xylene as measured in the breath of three volunteers after smoking. Breath values were 
normalized to the compound level detected just after smoking a cigarette. Vertical bars show the 
standard deviation obtained for the three breath samples evaluated. 
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Table 1. Target compounds in chromatographic elution order, and their quantifier and qualifier 
ions. Method detection limits (MDL) are indicated for the analysis of 775 cm3 of sample. 
 
Quantifier Qualifier MDL 
# Compound 
ion ions (pptv)* (ng·m-3) 
1 benzene 78 77, 51, 52 5 16 
2 2,5-dimethylfuran 96 95, 81, 53 5 20 
3 toluene 91 92 5 19 
4 m-, p-xylene 91 106, 105, 77 10 43 
5 o-xylene 91 106, 105, 77 10 43 
* values determined at 25ºC and 760 mm Hg. 
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Table 2. Median and quartiles [25 and 75%] for the analyte concentrations in the breath of 
smokers and non-smokers. Concentrations are expressed in ppbv. 
 
Compound 
Smokers 
(n=100) 
Non-smokers 
(n=104) 
P value 
benzene 7.366 [2.831, 23.091] 0.927 [0.289, 1.295] < 0.001 
2,5-dimethylfuran 0.978 [0.253, 3.186] 0.000 [0.000, 0.000]* < 0.001 
toluene 2.798 [0.830, 6.047] 1.208 [0.451, 2.350] < 0.001 
m-, p-xylene 0.101 [0.063, 0.168] 0.068 [0.047, 0.095] < 0.001 
o-xylene 0.045 [0.037, 0.071] 0.037 [0.034, 0.042] < 0.001 
* not detected (a value of 0 was used for statistical analysis). 
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Table 3. Spearman correlation coefficients for the compounds evaluated in smokers (n=100) and 
the daily intake of cigarettes, and the time since the last cigarette smoked. 
 
Compound 
Number of cigarettes smoked 
daily 
Time since last 
cigarette 
benzene 0.417 * -0.675 * 
2,5-dimethylfuran 0.417 * -0.721 * 
toluene 0.334 * -0.502 * 
m-, p-xylene 0.249 * -0.439 * 
o-xylene 0.251 * -0.293 * 
* significant
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Table 4. Median and quartiles [25 and 75%] for the analyte concentrations (ppbv) in the breath of smokers at different time intervals from the smoking of last cigarette. 
 time since last cigarette 
 ≥ 0 min ≥ 30 min ≥ 45 min ≥ 13 hours 
# smokers 100 58 43 15 
benzene 7.366 [2.831, 23.091] * 4.061 [1.941, 9.516] * 3.280 [1.507, 6.332] * 1.112 [0.667, 2.871] 
2,5-dimethylfuran 0.978 [0.253, 3.186] * 0.448 [0.131, 1.074] * 0.248 [0.101, 0.733] * 0.093 [0.039, 0.169] * 
toluene 2.798 [0.830, 6.047] * 1.546 [0.628, 4.029] * 1.312 [0.590, 3.058] 0.590 [0.310, 1.487] 
m-, p-xylene 0.101 [0.063, 0.168] * 0.082 [0.058,  0.146] * 0.073 [0.057, 0.118] 0.062 [0.046, 0.143] 
o-xylene 0.045 [0.037, 0.071] * 0.042 [0.035, 0.102] * 0.038 [0.035, 0.062] 0.036 [0.038, 0.047] 
* Significant differences with concentration values detected in non-smokers (see Table 2 for concentration values in the breath of non-smokers) 
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BREATH BIOMARKER ANALYSES IN SMOKERS  
(QUESTIONNAIRE) 
 
1. Age: 
2. Sex:  Male   Female  
3. Do you have any kind of pulmonary problem? No   Yes   If yes, please 
specify. 
4. Are you a smoker? No   Yes  (if you answered “no”, please go to question 8) 
5. Approximately how many cigarettes do you smoke per day? 
6. Which type of cigarettes do you smoke? (full flavor/black/light/cigars) 
7. How long has it been since you smoked your last cigarette? ____ days, ____ 
hours, ____ minutes. 
8. Have you consumed any drug in the last few days? No   Yes   Which type? 
9. Have you consumed any food in the last hour? No   Yes   If yes, please 
specify. 
10. Have you consumed any drink other than water during the last hour? No   Yes 
  Which? 
11. Have you had a coffee in the last hour? No   Yes  
12. Is there any history of lung cancer in your family? No    Yes  
13. Do you consider yourself to be in regular contact with smokers? No   Yes  (if 
you have answered “no”, there are no further questions.) 
14. Are these smokers friends or family members? 
15. How long do you consider yourself to be in contact with cigarette smoke during 
the day? 
 
Sample code: 
Sampling date: 
Time of sampling: 
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